Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced the approval of inducement awards for five new employees. The Compensation Committee of Avadel's Board of Directors granted non-statutory options to purchase 165,520 ordinary shares under the company's 2021 Inducement Plan.
The options come with a ten-year term and feature a four-year vesting schedule, with 25% vesting annually starting from each employee's first anniversary. These awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment acceptance.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha comunicato l'approvazione di premi di incentivazione per cinque nuovi dipendenti. Il Comitato per la Remunerazione del Consiglio di Amministrazione ha assegnato opzioni non statutarie per l'acquisto di 165.520 azioni ordinarie ai sensi del Piano di Induzione 2021 della società.
Le opzioni hanno una durata di dieci anni e prevedono un piano di maturazione quadriennale, con il 25% che matura ogni anno a partire dal primo anniversario dell'assunzione di ciascun dipendente. Queste assegnazioni sono state concesse in conformità alla Regola di quotazione Nasdaq 5635(c)(4) come incentivo per l'accettazione dell'impiego.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha anunciado la aprobación de premios de inducción para cinco nuevos empleados. El Comité de Compensación del Consejo de Administración concedió opciones no estatutarias para comprar 165.520 acciones ordinarias bajo el Plan de Inducción 2021 de la compañía.
Las opciones tienen un plazo de diez años y cuentan con un calendario de adquisición de derechos de cuatro años, con el 25% que se adquiere anualmente a partir del primer aniversario de cada empleado. Estas adjudicaciones se realizaron de conformidad con la Norma de Cotización de Nasdaq 5635(c)(4) como incentivo material para la aceptación del empleo.
Avadel Pharmaceuticals (Nasdaq: AVDL)는 다섯 명의 신입 직원에 대한 유인 보상 승인 소식을 발표했습니다. 이사회 보상위원회는 회사의 2021 유인 계획에 따라 165,520주 보통주를 매수할 수 있는 비법정 옵션을 부여했습니다.
옵션의 유효기간은 10년이며, 4년간의 베스팅 일정이 적용되어 각 직원의 채용 1주년부터 매년 25%씩 베스팅됩니다. 이 보상은 고용 수락을 유인하기 위한 중요 사항으로서 Nasdaq 상장 규정 5635(c)(4)에 따라 부여되었습니다.
Avadel Pharmaceuticals (Nasdaq: AVDL) a annoncé l'approbation d'attributions incitatives pour cinq nouveaux employés. Le comité de rémunération du conseil d'administration a accordé des options non statutaires d'achat de 165 520 actions ordinaires dans le cadre du plan d'inducement 2021 de la société.
Les options ont une durée de dix ans et sont assorties d'un calendrier d'acquisition des droits sur quatre ans, avec 25 % qui deviennent acquis chaque année à partir du premier anniversaire de chaque employé. Ces attributions ont été octroyées conformément à la règle d'inscription Nasdaq 5635(c)(4) comme incitation matérielle à accepter l'emploi.
Avadel Pharmaceuticals (Nasdaq: AVDL) hat die Genehmigung von Anreizzuteilungen für fünf neue Mitarbeiter bekanntgegeben. Das Vergütungskomitee des Vorstands gewährte nicht-statutory Optionen zum Kauf von 165.520 Stammaktien gemäß dem Inducement-Plan 2021 des Unternehmens.
Die Optionen haben eine Laufzeit von zehn Jahren und unterliegen einem vierjährigen Vesting-Plan, wobei 25 % jährlich mit dem ersten Jahrestag der jeweiligen Anstellung vesten. Diese Zuteilungen wurden gemäß Nasdaq-Listing-Regel 5635(c)(4) als wesentlicher Anreiz zur Annahme der Beschäftigung gewährt.
- None.
- None.
DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to five (5) new employees to purchase 165,520 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
What type of stock options did Avadel Pharmaceuticals (AVDL) grant to new employees?
What is the vesting schedule for Avadel's (AVDL) new employee stock options?
How long is the term of the stock options granted by Avadel (AVDL)?
Under which rule were Avadel's (AVDL) inducement awards granted?
